<DOC>
	<DOCNO>NCT00725621</DOCNO>
	<brief_summary>This prospective , open-label , 1-arm , multicenter observational study determine average Remicade dosage time span 9 infusion subject rheumatoid arthritis ( RA )</brief_summary>
	<brief_title>Real Life Dosing Remicade Rheumatoid Arthritis Austria Monitored Over 9 Infusions ( Study P03756 ) ( COMPLETED )</brief_title>
	<detailed_description>This study population choose non-probability sample .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Severe RA ( indication accord Austrian labeling ) . According Summary Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>